Record mula sa primary source
Decision-gradeTopline na resulta
REGENXBIO: inaasahan ang pivotal topline data ng RGX-202 sa unang bahagi ng Q2 2026
Inihayag ng kumpanya na ang mga pivotal topline na resulta mula sa confirmatory Phase I/II AFFINITY DUCHENNE trial ng RGX-202 ay inaasahan sa early Q2 2026. Patuloy ang enrollment sa confirmatory trial (n=30) at inaasahan na ang karamihan ng mga pasyente ay ma-enroll sa oras ng nakaplanong BLA submission.
Mahahalagang fact
- Na-file
- Mar 5, 2026, 12:30 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
RGNXREGENXBIO- Asset
- RGX-202
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts o RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026 - Robust patient enrollment continues in confirmatory trial o Surabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026 • Company to engage FDA on potential path forward for RGX-121 • Conference call today at 8:00 a.m. ET ROCKVILLE, Md., March 5, 2026 (PR Newswire) -- REGENXBIO
Higit pa tungkol sa asset na ito
Materyal
Hun 24, 2026
11:05 AM
RGNXREGENXBIO